FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985434534> ?p ?o ?g. }

• W1985434534 endingPage "1126" @default.
• W1985434534 startingPage "1118" @default.
• W1985434534 abstract "Background & Aims Given an appreciable risk of adverse-effects, current therapies for chronic hepatitis C virus (HCV) infection pose a dilemma to patients. We explored, via simulation modelling, patient-important benefits of attaining a sustained viral response (SVR). Methods We created the HCV Individualised Treatment-decision model (the HIT-model) to simulate, on a per patient basis, the lifetime course of HCV-related liver disease according to two distinct scenarios: (i) SVR attained, and (ii) SVR not attained. Then, for each model subject, the course of liver disease under these alternative scenarios was compared. The benefit of SVR was considered in terms of two patient-important outcomes: (1) the percent-probability that SVR confers additional life-years, and (2) the percent-probability that SVR confers additional healthy life-years, where “healthy” refers to years spent in compensated disease states (i.e., the avoidance of liver failure). Results The benefit of SVR varied strikingly. It was lowest for patients aged 60 years with initially mild fibrosis; 1.6% (95% CI: 0.8–2.7) and 2.9% (95% CI: 1.5–4.7) probability of gaining life-years and healthy life-years, respectively. Whereas it was highest for patients with initially compensated cirrhosis aged 30 years; 57.9% (95% CI: 46.0–69.0) and 67.1% (95% CI: 54.1–78.2) probability of gaining life-years and healthy life-years, respectively. Conclusions For older patients with less advanced liver fibrosis, SVR is less likely to confer benefit when measured in terms of averting liver failure and premature death. These data have important implications. Foremost, it may inform the contemporary patient dilemma of immediate treatment with existing therapies (that have poor adverse effect profiles) vs. awaiting future regimens that promise better tolerability. Given an appreciable risk of adverse-effects, current therapies for chronic hepatitis C virus (HCV) infection pose a dilemma to patients. We explored, via simulation modelling, patient-important benefits of attaining a sustained viral response (SVR). We created the HCV Individualised Treatment-decision model (the HIT-model) to simulate, on a per patient basis, the lifetime course of HCV-related liver disease according to two distinct scenarios: (i) SVR attained, and (ii) SVR not attained. Then, for each model subject, the course of liver disease under these alternative scenarios was compared. The benefit of SVR was considered in terms of two patient-important outcomes: (1) the percent-probability that SVR confers additional life-years, and (2) the percent-probability that SVR confers additional healthy life-years, where “healthy” refers to years spent in compensated disease states (i.e., the avoidance of liver failure). The benefit of SVR varied strikingly. It was lowest for patients aged 60 years with initially mild fibrosis; 1.6% (95% CI: 0.8–2.7) and 2.9% (95% CI: 1.5–4.7) probability of gaining life-years and healthy life-years, respectively. Whereas it was highest for patients with initially compensated cirrhosis aged 30 years; 57.9% (95% CI: 46.0–69.0) and 67.1% (95% CI: 54.1–78.2) probability of gaining life-years and healthy life-years, respectively. For older patients with less advanced liver fibrosis, SVR is less likely to confer benefit when measured in terms of averting liver failure and premature death. These data have important implications. Foremost, it may inform the contemporary patient dilemma of immediate treatment with existing therapies (that have poor adverse effect profiles) vs. awaiting future regimens that promise better tolerability." @default.
• W1985434534 created "2016-06-24" @default.
• W1985434534 creator A5004545282 @default.
• W1985434534 creator A5004579061 @default.
• W1985434534 creator A5007804720 @default.
• W1985434534 creator A5012931920 @default.
• W1985434534 creator A5051926617 @default.
• W1985434534 creator A5052742729 @default.
• W1985434534 creator A5062766650 @default.
• W1985434534 creator A5068122614 @default.
• W1985434534 creator A5069135365 @default.
• W1985434534 date "2014-06-01" @default.
• W1985434534 modified "2023-09-27" @default.
• W1985434534 title "Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model" @default.
• W1985434534 cites W1519408022 @default.
• W1985434534 cites W1964051982 @default.
• W1985434534 cites W1965358723 @default.
• W1985434534 cites W1968194021 @default.
• W1985434534 cites W1970494429 @default.
• W1985434534 cites W1972494982 @default.
• W1985434534 cites W1975600766 @default.
• W1985434534 cites W1981900811 @default.
• W1985434534 cites W1983480426 @default.
• W1985434534 cites W1984413237 @default.
• W1985434534 cites W2002795518 @default.
• W1985434534 cites W2003672974 @default.
• W1985434534 cites W2011437704 @default.
• W1985434534 cites W2014963784 @default.
• W1985434534 cites W2014989466 @default.
• W1985434534 cites W2016071077 @default.
• W1985434534 cites W2017766892 @default.
• W1985434534 cites W2020004919 @default.
• W1985434534 cites W2020856620 @default.
• W1985434534 cites W2026697567 @default.
• W1985434534 cites W2041643208 @default.
• W1985434534 cites W2042158802 @default.
• W1985434534 cites W2046552885 @default.
• W1985434534 cites W2047556186 @default.
• W1985434534 cites W2051406463 @default.
• W1985434534 cites W2053518656 @default.
• W1985434534 cites W2054882786 @default.
• W1985434534 cites W2056035602 @default.
• W1985434534 cites W2057494833 @default.
• W1985434534 cites W2058200448 @default.
• W1985434534 cites W2062458071 @default.
• W1985434534 cites W2070156507 @default.
• W1985434534 cites W2075157427 @default.
• W1985434534 cites W2093150448 @default.
• W1985434534 cites W2094963241 @default.
• W1985434534 cites W2098559033 @default.
• W1985434534 cites W2103723704 @default.
• W1985434534 cites W2111057508 @default.
• W1985434534 cites W2113576256 @default.
• W1985434534 cites W2113864802 @default.
• W1985434534 cites W2115399503 @default.
• W1985434534 cites W2122717211 @default.
• W1985434534 cites W2125897287 @default.
• W1985434534 cites W2125963799 @default.
• W1985434534 cites W2126454283 @default.
• W1985434534 cites W2131011125 @default.
• W1985434534 cites W2132667916 @default.
• W1985434534 cites W2135407654 @default.
• W1985434534 cites W2143549975 @default.
• W1985434534 cites W2143559032 @default.
• W1985434534 cites W2159234704 @default.
• W1985434534 cites W2162933087 @default.
• W1985434534 cites W2163731183 @default.
• W1985434534 cites W2164668044 @default.
• W1985434534 cites W2168957097 @default.
• W1985434534 cites W2319055243 @default.
• W1985434534 cites W3093727972 @default.
• W1985434534 cites W4211077792 @default.
• W1985434534 cites W4211260107 @default.
• W1985434534 cites W4233838513 @default.
• W1985434534 cites W4234409622 @default.
• W1985434534 cites W4244312606 @default.
• W1985434534 cites W4246639567 @default.
• W1985434534 doi "https://doi.org/10.1016/j.jhep.2014.01.020" @default.
• W1985434534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24509410" @default.
• W1985434534 hasPublicationYear "2014" @default.
• W1985434534 type Work @default.
• W1985434534 sameAs 1985434534 @default.
• W1985434534 citedByCount "17" @default.
• W1985434534 countsByYear W19854345342014 @default.
• W1985434534 countsByYear W19854345342015 @default.
• W1985434534 countsByYear W19854345342016 @default.
• W1985434534 countsByYear W19854345342017 @default.
• W1985434534 countsByYear W19854345342018 @default.
• W1985434534 countsByYear W19854345342021 @default.
• W1985434534 crossrefType "journal-article" @default.
• W1985434534 hasAuthorship W1985434534A5004545282 @default.
• W1985434534 hasAuthorship W1985434534A5004579061 @default.
• W1985434534 hasAuthorship W1985434534A5007804720 @default.
• W1985434534 hasAuthorship W1985434534A5012931920 @default.
• W1985434534 hasAuthorship W1985434534A5051926617 @default.
• W1985434534 hasAuthorship W1985434534A5052742729 @default.
• W1985434534 hasAuthorship W1985434534A5062766650 @default.
• W1985434534 hasAuthorship W1985434534A5068122614 @default.

• next